JPH05255069A - Vitamin preparation - Google Patents
Vitamin preparationInfo
- Publication number
- JPH05255069A JPH05255069A JP6012792A JP6012792A JPH05255069A JP H05255069 A JPH05255069 A JP H05255069A JP 6012792 A JP6012792 A JP 6012792A JP 6012792 A JP6012792 A JP 6012792A JP H05255069 A JPH05255069 A JP H05255069A
- Authority
- JP
- Japan
- Prior art keywords
- vitamin
- preparation
- leucine
- vitamins
- vitamin preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は安定な静注用総合ビタミ
ン製剤に関する。TECHNICAL FIELD The present invention relates to a stable intravenous multivitamin preparation.
【０００２】[0002]
【従来の技術】近年、医療の分野に於て著しい輸液療法
の進歩に伴い、安全に中心静脈にカテ−テルを留置する
高カロリ−輸液法の技術が確立され、何らかの理由で殆
ど経口摂取が困難または不可能な状態にある患者に対し
ての栄養管理が容易になりつつある。そしてそのために
人間に必要なビタミンを含有するビタミン製剤の存在が
必要不可欠になってきた。2. Description of the Related Art In recent years, with the remarkable progress of infusion therapy in the medical field, a technique of high calorie infusion method for safely placing a catheter in a central vein has been established, and for some reason, almost no oral intake is possible. Nutrition management is becoming easier for patients in difficult or impossible conditions. For that reason, the existence of vitamin preparations containing vitamins necessary for humans has become indispensable.
【０００３】[0003]
【発明が解決しようとする課題】しかし、従来ビタミン
はそれ自身不安定なものが多く、しかもこれらビタミン
を数種類混合した場合にこれら相互間で反応するものも
あり、長期に亙って保存するのが困難であると云う欠点
を有している。そのためビタミン製剤の安定化は製剤技
術上重要な課題となっている。However, conventional vitamins are often unstable in themselves, and some of them react with each other when several kinds of these vitamins are mixed, so that they are stored for a long period of time. Has the drawback of being difficult. Therefore, stabilization of vitamin preparations has become an important issue in the formulation technology.
【０００４】[0004]
【課題を解決しようとする手段】本発明者らは、安定な
静注用総合ビタミン製剤を開発すべく鋭意研究を重ねた
結果、上記の課題は以下の本発明により解決できること
見いだした。DISCLOSURE OF THE INVENTION As a result of intensive studies to develop a stable intravenous multivitamin preparation, the present inventors have found that the above problems can be solved by the present invention described below.
【０００５】本発明は、必須ビタミン１３種のうちの少
なくとも１種を含むビタミン群に、ロイシン、イソロイ
シン、メチオニン及びバリンからなる群から選ばれた少
なくとも１種を含有してなることを特徴とする、極めて
安定な静注用ビタミン製剤である。The present invention is characterized in that at least one selected from the group consisting of leucine, isoleucine, methionine and valine is contained in the vitamin group containing at least one of 13 essential vitamins. , A very stable intravenous vitamin preparation.
【０００６】本発明のビタミン製剤は、長期に亙る保存
にも極めて安定であり、ビタミン製剤としての価値は極
めて高い。The vitamin preparation of the present invention is extremely stable even during long-term storage, and is extremely valuable as a vitamin preparation.
【０００７】本発明において、ビタミンとは特に限定は
なく従来公知のものを広く使用でき、必須ビタミン１３
種のビタミンＡ、Ｂ1、Ｂ2、ニコチン酸アミド、パンテ
ノール、Ｂ6、葉酸、Ｂ12、Ｃ、Ｄ、Ｅ、ビオチン、
Ｋ、及びそれらの誘導体を含有していればよい。In the present invention, vitamins are not particularly limited, and conventionally known ones can be widely used. Essential vitamin 13
Species vitamins A, B 1 , B 2 , nicotinamide, panthenol, B 6 , folic acid, B 12 , C, D, E, biotin,
It suffices if it contains K and derivatives thereof.
【０００８】本発明のビタミン製剤に用いる上記各ビタ
ミンの組み合わせ及びその数は特に限定はない。The combination of the above-mentioned vitamins and the number thereof used in the vitamin preparation of the present invention are not particularly limited.
【０００９】本発明のビタミン製剤に含有されるべきビ
タミンの量としては特に制限はなく適宜選択することが
できる。例えばヒトに対する１日当りの必要量が、日本
静脈経腸栄養研修会誌 Ｖｏｌ．１３ Ｎｏ．４ ３１
７〜３２１頁（１９９１）等の文献に推奨値として記載
されており、１日当りの必要量が摂取されるように各種
ビタミンをビタミン製剤中に含有せしめておくのがよ
い。The amount of vitamin to be contained in the vitamin preparation of the present invention is not particularly limited and can be appropriately selected. For example, the daily required amount for humans is described in Japanese Journal of Parenteral and Enteral Nutrition Vol. 13 No. 4 31
It is described as a recommended value in the literature such as pages 7 to 321 (1991), and it is advisable to include various vitamins in the vitamin preparation so that the required amount per day is ingested.
【００１０】より具体的にはビタミンＡは２０００〜１
００００Ｉ．Ｕ．、ビタミンＢ1は０．５〜３０ｍｇ、
ビタミンＢ2は１〜２０ｍｇ、ビタミンＢ6は１〜５０ｍ
ｇ、ビタミンＢ12は１〜１００μｇ、ビタミンＣは３０
〜２０００ｍｇ、ナイアシンは５〜１００ｍｇ、パント
テン酸（パンテノ−ル）は１〜３０ｍｇ、葉酸は０．１
〜１０ｍｇ、ビオチンは５０〜１００００μｇ、ビタミ
ンＤは１００〜２０００Ｉ．Ｕ．、ビタミンＥは２〜１
００ｍｇ、ビタミンＫは１〜１５ｍｇをそれぞれ本発明
のビタミン製剤に含有させておくのが望ましい。More specifically, Vitamin A is 2000-1
0000I. U. , Vitamin B 1 is 0.5 to 30 mg,
Vitamin B 2 is 1 to 20 mg, Vitamin B 6 is 1 to 50 m
g, vitamin B 12 is 1 to 100 μg, vitamin C is 30
~ 2000 mg, niacin 5-100 mg, pantothenic acid (panthenol) 1-30 mg, folic acid 0.1
-10 mg, biotin 50-10,000 μg, vitamin D 100-2000 I.D. U. , Vitamin E is 2-1
00 mg and 1 to 15 mg of vitamin K are preferably contained in the vitamin preparation of the present invention.
【００１１】本発明において、安定化剤としてロイシ
ン、イソロイシン、メチオニン及びバリンからなる群か
ら選ばれた少なくとも１種（以下安定化剤という）をビ
タミンに添加するが、ロイシンとしてはＬ−ロイシン、
イソロイシンとしてはＬ−イソロイシン、メチオニンと
してはＬ−メチオニン、バリンとしてはＬ−バリンが望
ましい。In the present invention, at least one selected from the group consisting of leucine, isoleucine, methionine and valine (hereinafter referred to as a stabilizer) is added to the vitamin as a stabilizer, and as the leucine, L-leucine,
L-isoleucine is preferable as isoleucine, L-methionine is preferable as methionine, and L-valine is preferable as valine.
【００１２】本発明のビタミン製剤に配合すべき安定化
剤の量としては、特に制限がなく広い範囲から適宜選択
することができる。本発明では通常ビタミン製剤中に含
有される総ビタミン量に対して通常１０〜１０００重量
％、好ましくは２０〜５００重量％程度安定化剤を配合
するのがよい。The amount of the stabilizer to be added to the vitamin preparation of the present invention is not particularly limited and can be appropriately selected from a wide range. In the present invention, a stabilizer is usually added in an amount of usually 10 to 1000% by weight, preferably 20 to 500% by weight, based on the total amount of vitamins contained in the vitamin preparation.
【００１３】本発明のビタミン製剤の形態としては特に
制限がなく、例えば水溶液剤及び凍結乾燥品のいずれで
もよいが、凍結乾燥品の形態が特に好ましい。The form of the vitamin preparation of the present invention is not particularly limited and may be, for example, an aqueous solution or a lyophilized product, but the lyophilized product is particularly preferred.
【００１４】本発明のビタミン製剤の製造に当たっては
従来公知の方法をいずれも採用でき、例えば上記ビタミ
ンと安定化剤及び界面活性剤とを水に溶解することによ
り水溶液剤が製造され、またこの水溶液剤を通常の方法
に従い凍結乾燥することによって凍結乾燥品が製造され
る。In the production of the vitamin preparation of the present invention, any conventionally known method can be adopted. For example, an aqueous solution is produced by dissolving the above-mentioned vitamin, a stabilizer and a surfactant in water, and this aqueous solution is also used. A lyophilized product is produced by lyophilizing the agent according to a conventional method.
【００１５】また本発明のビタミン製剤の使用に際して
は、水溶液剤の場合はそのままで、凍結乾燥品の場合に
は注射用蒸留水や生理食塩水等で溶解して使用する。When the vitamin preparation of the present invention is used, the aqueous preparation is used as it is, and the freeze-dried product is dissolved in distilled water for injection or physiological saline.
【００１６】次に本発明の方法をさらに具体的に説明す
るために以下に実施例及び試験例を示す。尚実施例中の
ビタミン、安定化剤及び界面活性剤の％は水溶液に対す
る重量％である。Next, in order to describe the method of the present invention more specifically, examples and test examples are shown below. The percentages of vitamins, stabilizers and surfactants in the examples are% by weight based on the aqueous solution.
【００１７】[0017]
（実施例１）水酸化ナトリウムでｐＨ４．８〜５．２に
調製した、塩酸チアミン（ビタミンＢ1）０．２％、リ
ン酸リボフラビンナトリウム（ビタミンＢ2）０．２
％、塩酸ピリドキシン（ビタミンＢ6）０．２％、ニコ
チン酸アミド１．６％、シアノコバラミン（ビタミンＢ
12）０．０００４％、葉酸０．０１６％、パンテノ−ル
０．６％、アスコルビン酸（ビタミンＣ）４．０％、ビ
オチン０．４％、パルミチン酸レチノ−ル（ビタミン
Ａ）４０００Ｉ．Ｕ．、エルゴカルシフェロ−ル（ビタ
ミンＤ3）４００Ｉ．Ｕ．、酢酸トコフェロ−ル０．６
％、フィトナジオン（ビタミンＫ1）０．８％、ポリソ
リベ−ト８０ ２．４％、Ｌ−ロイシン１．５％を含む
水溶液を適当な容器（例えば１０ｍｌバイアル）に充填
し、凍結乾燥後、不活性なガスで置換し、封栓してビタ
ミン製剤（１）を得た。Example 1 Thiamine hydrochloride (vitamin B 1 ) 0.2%, riboflavin sodium phosphate (vitamin B 2 ) 0.2, adjusted to pH 4.8 to 5.2 with sodium hydroxide.
%, Pyridoxine hydrochloride (vitamin B 6 ) 0.2%, nicotinamide 1.6%, cyanocobalamin (vitamin B 6
12 ) 0.0004%, folic acid 0.016%, panthenol 0.6%, ascorbic acid (vitamin C) 4.0%, biotin 0.4%, retino palmitate (vitamin A) 4000I. U. , Ergo calcivirus Ferro - Le (vitamin D 3) 400I. U. , Tocopheryl acetate 0.6
%, Phytonadione (vitamin K 1 ) 0.8%, polysorbate 80 2.4%, and L-leucine 1.5% were filled in an appropriate container (for example, 10 ml vial) and freeze-dried. After substituting with an active gas and sealing, a vitamin preparation (1) was obtained.
【００１８】（実施例２）安定化剤としてＬ−ロイシン
１．５％の代わりにＬ−ロイシン１．０％を加える他
は、実施例１と同様に処理してビタミン製剤（２）を得
た。(Example 2) A vitamin preparation (2) was obtained in the same manner as in Example 1 except that 1.0% of L-leucine was added as a stabilizer instead of 1.5% of L-leucine. It was
【００１９】（実施例３）安定化剤としてＬ−ロイシン
１．５％の代わりにＬ−イソロイシン１．０％を加える
他は、実施例１と同様に処理してビタミン製剤（３）を
得た。Example 3 A vitamin preparation (3) was obtained by the same procedure as in Example 1 except that 1.0% of L-isoleucine was added as a stabilizer instead of 1.5% of L-leucine. It was
【００２０】（実施例４）安定化剤としてＬ−ロイシン
１．５％の代わりにＬ−メチオニン１．０％を加える他
は、実施例１と同様に処理してビタミン製剤（４）を得
た。Example 4 A vitamin preparation (4) was obtained in the same manner as in Example 1 except that L-methionine 1.0% was added instead of L-leucine 1.5% as a stabilizer. It was
【００２１】（実施例５）安定化剤としてＬ−ロイシン
１．５％の代わりにＬ−バリン１．０％を加える他は、
実施例１と同様に処理してビタミン製剤（５）を得た。Example 5: L-valine 1.0% was added instead of L-leucine 1.5% as a stabilizer,
A vitamin preparation (5) was obtained by treating in the same manner as in Example 1.
【００２２】（実施例６）水酸化ナトリウムでｐＨ４．
８〜５．２に調製した、硝酸チアミン（ビタミンＢ1）
０．２％、リン酸リボフラビンナトリウム（ビタミンＢ
2）０．２％、塩酸ピリドキシン（ビタミンＢ6）０．２
％、ニコチン酸アミド１．６％、シアノコバラミン（ビ
タミンＢ12）０．０００４％、葉酸０．０１６％、パン
トテン酸カルシウム０．６％、アスコルビン酸（ビタミ
ンＣ）４．０％、ビオチン０．４％、パルミチン酸レチ
ノ−ル（ビタミンＡ）３３００Ｉ．Ｕ．、コレカルシフ
ェロ−ル（ビタミンＤ2）４００Ｉ．Ｕ．、酢酸トコフ
ェロ−ル０．６％、メナテトレノン（ビタミンＫ2）
０．８％、ポリソリベ−ト８０ ２．４％、Ｌ−ロイシ
ン１．５％を含む水溶液を適当な容器（例えば１０ｍｌ
バイアル）に充填し、凍結乾燥後、不活性なガスで置換
し、封栓してビタミン製剤（６）を得た。(Example 6) pH of 4.
Thiamine nitrate (vitamin B 1 ) prepared to 8-5.2
0.2%, riboflavin sodium phosphate (vitamin B
2 ) 0.2%, pyridoxine hydrochloride (vitamin B 6 ) 0.2
%, Nicotinamide 1.6%, cyanocobalamin (vitamin B 12 ) 0.0004%, folic acid 0.016%, calcium pantothenate 0.6%, ascorbic acid (vitamin C) 4.0%, biotin 0.4 %, Retinol palmitate (vitamin A) 3300 I.%. U. , Cholecalciferol (vitamin D 2 ) 400I. U. , Tocopherol acetate 0.6%, menatetrenone (vitamin K 2 )
An aqueous solution containing 0.8%, polysorbate 80 2.4%, and L-leucine 1.5% was put in a suitable container (for example, 10 ml).
Vial), lyophilized, replaced with an inert gas, and sealed to obtain a vitamin preparation (6).
【００２３】（実施例７）安定化剤としてＬ−ロイシン
１．５％の代わりにＬ−ロイシン１．０％を加える他
は、実施例６と同様に処理してビタミン製剤（７）を得
た。Example 7 A vitamin preparation (7) was obtained by the same procedure as in Example 6 except that 1.0% of L-leucine was added as a stabilizer instead of 1.5% of L-leucine. It was
【００２４】（実施例８）安定化剤としてＬ−ロイシン
１．５％の代わりにＬ−イソロイシン１．０％を加える
他は、実施例６と同様に処理してビタミン製剤（８）を
得た。(Example 8) A vitamin preparation (8) was obtained by the same procedure as in Example 6 except that 1.0% of L-isoleucine was added as a stabilizer instead of 1.5% of L-leucine. It was
【００２５】（実施例９）安定化剤としてＬ−ロイシン
１．５％の代わりにＬ−メチオニン１．０％を加える他
は、実施例６と同様に処理してビタミン製剤（９）を得
た。(Example 9) A vitamin preparation (9) was obtained by the same procedure as in Example 6 except that 1.0% of L-methionine was added as a stabilizer instead of 1.5% of L-leucine. It was
【００２６】（実施例１０）安定化剤としてＬ−ロイシ
ン１．５％の代わりにＬ−バリン１．０％を加える他
は、実施例６と同様に処理してビタミン製剤（１０）を
得た。Example 10 A vitamin preparation (10) was obtained by the same procedure as in Example 6 except that 1.0% of L-valine was added as a stabilizer instead of 1.5% of L-leucine. It was
【００２７】（実施例１１）水酸化ナトリウムでｐＨ
４．８〜５．２に調製した、塩酸チアミン（ビタミンＢ
1）０．２％、リン酸リボフラビンナトリウム（ビタミ
ンＢ2）０．２％、塩酸ピリドキシン（ビタミンＢ6）
０．２％、ニコチン酸アミド１．６％、シアノコバラミ
ン（ビタミンＢ12）０．０００４％、葉酸０．０１６
％、パンテノール０．６％、アスコルビン酸（ビタミン
Ｃ）４．０％、ビオチン０．４％、Ｌ−ロイシン１．５
％を含む水溶液を適当な容器（例えば１０ｍｌバイア
ル）に充填し、凍結乾燥後、不活性なガスで置換し、封
栓してビタミン製剤（１１）を得た。(Example 11) pH with sodium hydroxide
Thiamine hydrochloride (vitamin B prepared in 4.8 to 5.2)
1 ) 0.2%, riboflavin sodium phosphate (vitamin B 2 ) 0.2%, pyridoxine hydrochloride (vitamin B 6 ).
0.2%, nicotinamide 1.6%, cyanocobalamin (vitamin B 12 ) 0.0004%, folic acid 0.016
%, Panthenol 0.6%, ascorbic acid (vitamin C) 4.0%, biotin 0.4%, L-leucine 1.5
An aqueous solution containing 10% was filled in an appropriate container (for example, 10 ml vial), lyophilized, replaced with an inert gas, and sealed to obtain a vitamin preparation (11).
【００２８】（実施例１２）安定化剤としてＬ−ロイシ
ン１．５％の代わりにＬ−ロイシン１．０％を加える他
は、実施例１１と同様に処理してビタミン製剤（１２）
を得た。(Example 12) A vitamin preparation (12) was prepared in the same manner as in Example 11 except that 1.0% of L-leucine was added instead of 1.5% of L-leucine as a stabilizer.
Got
【００２９】（実施例１３）安定化剤としてＬ−ロイシ
ン１．５％の代わりにＬ−イソロイシン１．０％を加え
る他は、実施例１１と同様に処理してビタミン製剤（１
３）を得た。Example 13 A vitamin preparation (1) was prepared in the same manner as in Example 11 except that 1.0% of L-isoleucine was added as a stabilizer instead of 1.5% of L-leucine.
3) was obtained.
【００３０】（実施例１４）安定化剤としてＬ−ロイシ
ン１．５％の代わりにＬ−メチオニン１．０％を加える
他は、実施例１１と同様に処理してビタミン製剤（１
４）を得た。(Example 14) A vitamin preparation (1) was prepared in the same manner as in Example 11 except that 1.0% of L-methionine was added as a stabilizer instead of 1.5% of L-leucine.
4) was obtained.
【００３１】（実施例１５）安定化剤としてＬ−ロイシ
ン１．５％の代わりにＬ−バリン１．０％を加える他
は、実施例１１と同様に処理してビタミン製剤（１５）
を得た。(Example 15) A vitamin preparation (15) was prepared in the same manner as in Example 11 except that 1.0% of L-valine was added as a stabilizer instead of 1.5% of L-leucine.
Got
【００３２】（比較例１）安定化剤を加えない他は、実
施例１と同様に処理してビタミン製剤（１６）を得た。Comparative Example 1 A vitamin preparation (16) was obtained in the same manner as in Example 1 except that the stabilizer was not added.
【００３３】（比較例２）安定化剤を加えない他は、実
施例６と同様に処理してビタミン製剤（１７）を得た。Comparative Example 2 A vitamin preparation (17) was obtained by the same treatment as in Example 6 except that the stabilizer was not added.
【００３４】（比較例３）安定化剤を加えない他は、実
施例１１と同様に処理してビタミン製剤（１８）を得
た。Comparative Example 3 A vitamin preparation (18) was obtained in the same manner as in Example 11 except that the stabilizer was not added.
【００３５】（実施例１６）上記の各実施例及び比較例
で得られたビタミン製剤につき、日本ビタミン学会編ビ
タミン学実験法I，IIに記載されている方法を参考に安
定性試験を行った。結果を下記表１、表２及び表３に示
す。尚、表における数値は、ビタミン製剤中の各ビタミ
ンの残存率（％）である。Example 16 A stability test was conducted on the vitamin preparations obtained in each of the above Examples and Comparative Examples with reference to the methods described in Vitaminology Experimental Methods I and II, edited by the Vitamin Society of Japan. .. The results are shown in Table 1, Table 2 and Table 3 below. In addition, the numerical value in the table is the residual rate (%) of each vitamin in the vitamin preparation.
【表１】 [Table 1]
【表２】 [Table 2]
【表３】 表１、表２及び表３に示すように、実施例１〜１５によ
り得た本発明のビタミン製剤は、比較例１〜３に比べ優
れたビタミンの安定性を示した。[Table 3] As shown in Table 1, Table 2 and Table 3, the vitamin preparations of the present invention obtained in Examples 1 to 15 showed superior stability of vitamins as compared with Comparative Examples 1 to 3.
【００３６】[0036]
【発明の効果】本発明のビタミン製剤は、優れたビタミ
ン安定性を有し、長期保存が可能な静注用ビタミン製剤
として有効である。INDUSTRIAL APPLICABILITY The vitamin preparation of the present invention has excellent vitamin stability and is effective as an intravenous vitamin preparation capable of long-term storage.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.5 識別記号 庁内整理番号 ＦＩ 技術表示箇所 Ａ６１Ｋ 31/215 8413−4Ｃ 31/355 7252−4Ｃ 31/375 7252−4Ｃ 31/505 7252−4Ｃ 31/59 7252−4Ｃ 47/18 Ｊ 7433−4Ｃ (72)発明者 渡辺 純一郎 神奈川県足柄上郡中井町井ノ口1500番地 テルモ株式会社内─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 5 Identification code Internal reference number FI Technical display location A61K 31/215 8413-4C 31/355 7252-4C 31/375 7252-4C 31/505 7252-4C 31/59 7252-4C 47/18 J 7433-4C (72) Inventor Junichiro Watanabe 1500 Inoguchi, Nakai-cho, Ashigarakami-gun, Kanagawa Terumo Corporation
Claims (1)
１種を含むビタミン群に、ロイシン、イソロイシン、メ
チオニン及びバリンからなる群から選ばれた少なくとも
１種を含有してなることを特徴とする静注用ビタミン製
剤。1. An intravenous injection characterized by containing at least one selected from the group consisting of leucine, isoleucine, methionine and valine in a vitamin group containing at least one of 13 essential vitamins. Vitamin preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6012792A JPH05255069A (en) | 1992-03-17 | 1992-03-17 | Vitamin preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6012792A JPH05255069A (en) | 1992-03-17 | 1992-03-17 | Vitamin preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH05255069A true JPH05255069A (en) | 1993-10-05 |
Family
ID=13133162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP6012792A Pending JPH05255069A (en) | 1992-03-17 | 1992-03-17 | Vitamin preparation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH05255069A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999037167A3 (en) * | 1998-01-22 | 1999-09-30 | Abbott Lab | Process of improving the stability of vitamin d in a nutritional product containing hydrolyzed protein and product produced thereby |
| JP2005325080A (en) * | 2004-05-17 | 2005-11-24 | Daiichi Fine Chemical Co Ltd | Composition containing calcium pantothenate and vitamins |
| CN100361659C (en) * | 2005-01-12 | 2008-01-16 | 无锡凯夫制药有限公司 | Composite vitamin B powdery injection for venous infusion and preparation thereof |
| JP2015010060A (en) * | 2013-06-28 | 2015-01-19 | ロート製薬株式会社 | Pharmaceutical composition |
| JP2018123081A (en) * | 2017-01-31 | 2018-08-09 | 中外製薬株式会社 | Aqueous pharmaceutical composition containing vitamin d compound |
| CN108815166A (en) * | 2018-08-16 | 2018-11-16 | 济南康和医药科技有限公司 | A kind of Compound vitamine injection and preparation method thereof |
-
1992
- 1992-03-17 JP JP6012792A patent/JPH05255069A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999037167A3 (en) * | 1998-01-22 | 1999-09-30 | Abbott Lab | Process of improving the stability of vitamin d in a nutritional product containing hydrolyzed protein and product produced thereby |
| JP2005325080A (en) * | 2004-05-17 | 2005-11-24 | Daiichi Fine Chemical Co Ltd | Composition containing calcium pantothenate and vitamins |
| CN100361659C (en) * | 2005-01-12 | 2008-01-16 | 无锡凯夫制药有限公司 | Composite vitamin B powdery injection for venous infusion and preparation thereof |
| JP2015010060A (en) * | 2013-06-28 | 2015-01-19 | ロート製薬株式会社 | Pharmaceutical composition |
| JP2018123081A (en) * | 2017-01-31 | 2018-08-09 | 中外製薬株式会社 | Aqueous pharmaceutical composition containing vitamin d compound |
| CN108815166A (en) * | 2018-08-16 | 2018-11-16 | 济南康和医药科技有限公司 | A kind of Compound vitamine injection and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2569949T3 (en) | Pharmaceutical formulations comprising a peptide complexed with a diketopiperazine | |
| US5569670A (en) | Combination medications containing alpha-lipoic acid and related | |
| WO2003068209A1 (en) | Metformin salts of lipophilic acids | |
| CO4700482A1 (en) | FORMULATIONS OF A MONOMER INSULIN ANALOG | |
| EP0225189A3 (en) | Targeted enteral delivery system | |
| PL198132B1 (en) | Moxifloxacin formulation containing common salt | |
| JP2004217669A (en) | Anti-diabetic pharmaceutical and method for production of the same | |
| WO2018167627A1 (en) | Pharmaceutical composition of oral suspension of anti-neoplastic alkylating agents | |
| EP1641460A2 (en) | Stable 5, 10-methylene-tetrahydrofolate pharmaceutical compounds | |
| KR880005933A (en) | Vitamin B6-Containing Pharmaceutical Formulations | |
| EP0502313B1 (en) | Method for insuring adequate intracellular glutathione in tissue | |
| JPH05255069A (en) | Vitamin preparation | |
| JP3195360B2 (en) | Pharmaceutical composition containing tiagabine hydrochloride and method for producing the same | |
| US5491150A (en) | Supplementary therpeutic agents for the treatment of immunodeficiency syndrome | |
| AU2004314154B2 (en) | Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same | |
| KR101924786B1 (en) | Pharmaceutical composition of ibuprofen for injection | |
| KR20060066732A (en) | Multivitamin syrup for children or young adults | |
| JP3182564B2 (en) | Nutrition composition | |
| EP0003682B1 (en) | Process for solubilizing an insoluble drug and an aqueous solution prepared by this process | |
| Barker et al. | Folic acid and total parenteral nutrition | |
| JPH0337521B2 (en) | ||
| JPS59204116A (en) | Vitamine composition | |
| JPH07116031B2 (en) | Anti-cancer drug | |
| JP3155312B2 (en) | Stable intravenous multivitamin preparation | |
| JP2003514014A5 (en) |